Green Signal for Alembic: Rivaroxaban Tablets Cleared for Takeoff in the US

Unknown Apr 02, 2026 1,150 Views

Alembic Pharmaceuticals has achieved final US Food and Drug Administration (USFDA) approvals for its Rivaroxaban tablets, which is an important achievement by the company in the high-value US generics industry. The four strengths are covered by the approvals and place Alembic at a position where...

Details of the Approval

Alembic got final USFDA approval for Rivaroxaban tablets in strengths of 2.5 mg, 10 mg, 15 mg, and 20 mg.
Launch of the strength of 2.5 mg is expected by the company in Q1 of FY26.

Market Opportunity

Generic Rivaroxaban is an oral anticoagulant market leader that prevents and treats blood clots, prevents stroke, and treats deep vein thrombosis and pulmonary embolism.
The US market size for Rivaroxaban tablets (10 mg, 15 mg, and 20 mg) was estimated at around $6.1 billion during the 12 months ended March 2020.
The 2.5 mg strength alone is a $447 million opportunity in the US, with the overall market for all strengths worth $8.5 billion as of early 2025.

Strategic Impact for Alembic

With this approval, Alembic further strengthens its US generics portfolio, having a total of 124 USFDA approvals (110 final and 14 tentative).
The launch is anticipated to significantly boost Alembic's revenue and market share within the US pharma industry.

Stock Market Reaction

With earlier announcements on Rivaroxaban approvals, the share price of Alembic Pharma has consistently made significant gains, demonstrating investor faith in its US growth strategy.

Conclusion

Alembic Pharma's second and last USFDA clearance of Rivaroxaban tablets in various strengths is a big win, opening the gates to a highly priced market and further strengthening the company's presence in the global generic market.

Sources: Business Upturn, Business Today, Business Standard, Bajaj Broking

Stay Ahead – Explore Now! Wanbury Expands Global Footprint with New API Regulatory Filings